Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Telix Pharmaceuticals Limited: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Telix Pharmaceuticals Limited
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Telix Pharmaceuticals Limited
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 793.65 and 88.07 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Telix Pharmaceuticals Limited SectorAustralia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Telix Pharmaceuticals Limited SectorAustralia

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Telix Pharmaceuticals Limited SectorAustralia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Telix Pharmaceuticals Limited SectorAustralia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Telix Pharmaceuticals Limited SectorAustralia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.42B
A
43.14B
AAA
33.02B -
31.32B -
B
- -
28.9B
AAA
25.34B
A
14.78B - - - - -
13.35B - - - - - - -
12.5B
AA
11.99B
BBB
Average 21.78B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. TLX Stock
  4. Ratings Telix Pharmaceuticals Limited